9803928-2

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 41/00 // (A61K 41/00, 31:335, 31:675, 31:70, 33:24)

A1

(11) International Publication Number: WO 97/26915

(43) International Publication Date: 31 July 1997 (31.07.97)

(21) International Application Number: PCT/US97/00907

(22) International Filing Date: 23 January 1997 (23.01.97)

(30) Priority Data:
08/591,318 25 January 1996 (25.01.96) US

(60) Parent Application or Grant
(63) Related by Continuation
US 08/591,318 (CIP)
Filed on 25 January 1996 (25.01.96)

(71) Applicant *(for all designated States except US)*: PHARMACYCLICS, INC. [US/US]; 995 East Arques Avenue, Sunnyvale, CA 94086-4521 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: MILLER, Richard, A. [US/US]; 250 Golden Hills Drive, Portola Valley, CA 94028 (US). YOUNG, Stuart, W. [US/US]; 45 Las Piedras, Portola Valley, CA 94028 (US).

(74) Agent: NORBERG, Gloria, L.; Akin, Gump, Strauss, Hauer & Feld, L.L.P., Suite 1900, 816 Congress Avenue, Austin, TX 78701 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: USE OF A THEXAPHYRIN IN THE PREPARATION OF A MEDICAMENT FOR USE WITH A CHEMOTHERAPEUTIC AGENT IN CANCER CHEMOSENSITIZATION

(57) Abstract

Methods for cancer chemosensitization are provided. Texaphyrins are new chemosensitizers for enhancing the cytotoxicity of chemotherapeutic agents. The enhancement appears to be P-glycoprotein-independent since texaphyrins are effective in both a P-glycoprotein-expressing and a P-glycoprotein-nonexpressing cell line. Methods are provided for the treatment of cancers such as leukemia, lymphoma, carcinoma, and sarcoma using a texaphyrin as a chemosensitizer.